IDIrene Duba

Irene Duba

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Irene Duba has a total of 167 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    A national ecosystem for long-read genome sequencing: Integrating population genomics and rare disease diagnostics in Sweden

    by Adam Ameur, Fulya Taylan, Marlene Ek, Jesper Eisfeldt, Susana Häggqvist, Maria Pettersson, Ignas Bunikis, Joakim Klar, Ida Höijer, Maria Strandh, et al.

    To evaluate the clinical implementation of long-read genome sequencing (lrGS) and establish the population reference resources needed to support its use in diagnostics, we integrate two complementary initiatives: Genome of Sweden (GoS), Sweden’s contribution to Genome of Europe (GoE), and the Genomic Medicine Sweden – Rare Diseases (GMS-RD) long-read sequencing pilot. The initial GoS release of 576 individuals provides population-scale maps of genetic and epigenetic variation. Among 485 GMS-RD probands, 161 (33.2%) receive a molecular diagnosis, with lrGS providing added clinical value in 40 (24.8%). As a first-line test, lrGS could have avoided at least 42 follow-up analyses and an additional testing cycle in 7.2% of probands, reducing costs and the burden on patients. By integrating population and clinical long-read genomics, Sweden establishes a national ecosystem for genomic research and clinical diagnostics. Our findings support the clinical implementation of lrGS and offer a scalable model for national collaboration.

  • Open Access

    CDK4/6 inhibition induces a senescence-associated secretory phenotype via delayed NF-κB activation

    by Joanna Lan-Hing Yeung, Justin Rendleman, Lauren Anderson Westcott, Arnold Ou, Matthew Pressler, Nicole Pagane, Irene Duba, Ria Hosuru, Bat-Ider Tumenbayar, Viviana I Risca

    Cellular senescence consists of regulated phenotypes associated with permanent exit from the cell cycle in response to stressors such as genomic instability. The consequences of senescence go beyond individual cells because of the senescence-associated secretory phenotype (SASP), which can induce inflammation in neighboring cells. Some cancers respond to CDK4/6 inhibitors (CDK4/6i) with a senescence-like phenotype in the absence of extensive DNA damage. We asked how the SASP and the transcriptional regulatory profile triggered by CDK4/6i-driven arrest compare with the canonical NF-κB–regulated SASP triggered by DNA damage. We profiled the dynamics of transcriptional regulation in response to the CDK4/6i, palbociclib, and the DNA-damaging agent, doxorubicin. We found that up-regulation of NF-κB–driven SASP genes was shared across both drugs, although delayed in CDK4/6i, coinciding with slower enhancer activation and epigenetic changes. ATM/ATR inhibition did not affect CDK4/6i-induced NF-κB nuclear localization, suggesting an alternative upstream activator. Inhibiting NF-κB suppressed the expression of SASP genes without reversing stable arrest, pointing to SASP manipulation as a potential therapeutic strategy and providing insights into controversies regarding cell cycle arrest–driven SASP.

  • Top Cited Papers
    Open Access

    Biallelic variants in RNU2-2 cause a remarkably frequent developmental and epileptic encephalopathy

    by Adam Jackson, Alexander J. M. Blakes, Bader Alhaddad, Olivia J. Henry, Angelica M. Delgado-Vega, Elizabeth Wall, Ola Abdelhadi, Shakti Agrawal, Khadijah Bakur, Edward Blair, et al.

    Neurodevelopmental disorders (NDDs) affect 2–4% of the population, are predominantly genetic and remain unsolved in ~50% of individuals. We show that rare biallelic variants in RNU2-2 are enriched and over-transmitted in individuals with unresolved NDDs. We define a recessive RNU2-2 syndrome, delineate its unique genetic architecture and show that it manifests clinically as a severe developmental and epileptic encephalopathy. We find that candidate biallelic variants are significantly correlated with reduced U2-2 abundance, implicating compromised transcript stability as a probable pathomechanism. We identify a decreased ratio of U2-2 to its paralog U2-1 as a potential diagnostic biomarker for this condition. We show that the recessive RNU2-2 syndrome is genetically, clinically and mechanistically distinct from the dominant RNU2-2 disorder. Within our cohort, the recessive RNU2-2 syndrome emerges as by far the most frequent recessive NDD, greatly disproportionate to the small genomic footprint of this non-protein-coding gene.


  • Open Access

    CDK4/6 inhibition induces a DNA damage-independent senescence-associated secretory phenotype driven by delayed activation of NF-κB

    by Joanna Lan-Hing Yeung, Justin Rendleman, Lauren Anderson Westcott, Arnold Ou, Matthew Pressler, Nicole Pagane, Irene Duba, Ria Hosuru, Bat-Ider Tumenbayar, Viviana I. Risca

    Cellular senescence consists of regulated cell phenotypes associated with permanent exit from the cell cycle in response to stressors such as genomic instability. The consequences of senescence go beyond individual cells due to the senescence associated secretory phenotype (SASP), which can induce inflammation in neighboring cells. Some cancers respond to CDK4/6 inhibitors (CDK4/6i)—a family of targeted therapies that inhibit proliferation—with a senescence-like phenotype in the absence of DNA damage. We asked how the SASP and the transcriptional regulatory profile triggered by CDK4/6i-driven arrest compares to the canonical NF-κB-regulated SASP triggered by DNA damage. We profiled the temporal dynamics of transcriptional regulation in response to the CDK4/6i, palbociclib, and the DNA damaging agent, doxorubicin. We found that, although upregulation of NF-κB driven-SASP genes is shared across both drugs, it is delayed in CDK4/6i. This coincides with slower enhancer activation and epigenetic changes. Interestingly, ATM/ATR inhibition does not affect CDK4/6i-induced NF-κB nuclear localization, pointing to an alternative mechanism driving NF-κB activity in the absence of DNA damage. Inhibiting NF-κB suppresses the expression of shared SASP genes without reversing stable arrest. This points to SASP manipulation as a potential therapeutic strategy, and resolves an ongoing controversy about the nature of cell cycle arrest-driven SASP.